Skip to main content
HR 5547 118th Congress House Health Genetics Medicare Prescription drugs

Maintaining Investments in New Innovation Act

Introduced: December 11, 2023 See on congress.gov
This bill died when the 118th Congress ended
It never became law before the 118th Congress (2023–2024) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 4 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 17, 2024
Referred to the Subcommittee on Health.
Sep 22, 2023
Referred to the Subcommittee on Health.
Sep 18, 2023
Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Sep 18, 2023
Introduced in House
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Plain-English summary Congressional Research Service

Maintaining Investments in New Innovation Act

This bill requires drug products with genetically targeted technology to have had market approval for at least 11 years in order to qualify for the Medicare Drug Price Negotiation Program. (The program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation.)

What's happening now December 17, 2024

Referred to the Subcommittee on Health.

 Related & companion bills 1
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 4
 Lobbying activity 5

Registered lobbyists who named this bill in their disclosure filings. Source: federal Lobbying Disclosure Act filings.

  • LMH STRATEGIC SOLUTIONS
    for IONIS PHARMACEUTICALS, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2025
  • HARMONY BIOSCIENCES
    for HARMONY BIOSCIENCES · Pennsylvania · 1st Quarter (Jan 1 - Mar 31) 2025
  • TIBER CREEK HEALTH STRATEGIES, INC.
    for NOVARTIS · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2025
  • FORBES-TATE
    for NOVARTIS, INC. · District of Columbia · 1st Quarter (Jan 1 - Mar 31) 2025
  • FORBES-TATE
    for IONIS PHARMACEUTICAL, INC. · California · 1st Quarter (Jan 1 - Mar 31) 2025
Cite this page click to expand
APA
U.S. Congress. (2026). H.R. 5547: Maintaining Investments in New Innovation Act. 118th Congress. Open America. https://openamerica.io/bill/118-HR-5547/
MLA
"H.R. 5547: Maintaining Investments in New Innovation Act." 118th Congress, 2026, Open America, https://openamerica.io/bill/118-HR-5547/.
Bluebook (legal)
H.R. 5547, 118th Cong. (2026), https://openamerica.io/bill/118-HR-5547/.
Markdown link
[H.R. 5547: Maintaining Investments in New Innovation Act](https://openamerica.io/bill/118-HR-5547/)
Report a problem